Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4733-4744

  Campion, Jeffrey J ^a   McNamara, Patrick J ^b   Evans, Martin E ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; GENETIC VARIABILITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STEADY STATE;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; KINETICS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RESERPINE; STAPHYLOCOCCUS AUREUS;

EID: 9644287940     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4733-4744.2004     Document Type: Article

References (62)

1. Andersson, D. I., and B. R. Levin. 1999. The biological costs of antibiotic resistance. Curr. Opin. Microbiol. 2:489-493.
2. Baquero, F., and M. C. Negri. 1997. Selective compartments for resistant microorganisms in antibiotic gradients. BioEssays 19:731-736.
3. Baquero, F., M. C. Negri, M. I. Morosini, and J. Blázquez. 1998. Antibiotic-selective environments. Clin. Infect. Dis. 27(Suppl. 1):S5-S11.
4. Baquero, F., M. C. Negri, M. I. Morosini, and J. Blázquez. 1997. The antibiotic selective process: concentration-specific amplification of low-level populations, p. 93-111. In S. B. Levy (ed.), Antibiotic resistance: origins, evolution, and spread. John Wiley & Sons, New York, N.Y.
5. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
6. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
7. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
8. Brockbank, S. M. V., and P. T. Barth. 1993. Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus. J. Bacteriol. 175:3269-3277.
9. Campion, J. J., M. E. Evans, and P. J. McNamara. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother., in press.
10. Catchpole, C., J. M. Andrews, J. Woodcock, and R. Wise. 1994. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J. Antimicrob. Chemother. 33:103-110.
11. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, M. Beach, and the SENTRY Participants Group. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S114-S132.
12. Dong, Y., X. Zhao, J. Domagala, and K. Drlica. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758.
13. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
14. Evans, M. E., and W. B. Titlow. 1998. Selection of fluoroquinolone- resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin. Antimicrob. Agents Chemother. 42:727.
15. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
16. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
17. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
18. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
19. Fournier, B., and D. C. Hooper. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotrophic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:121-128.
20. Gihaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
21. Gilbert, D. N., S. J. Kohlhepp, K. A. Slama, G. Gurnkemeier, G. Lewis, R. J. Dworkin, S. E. Slaughter, and J. E. Legett. 2001. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob. Agents Chemother. 45:883-892.
22. Gootz, T. D., and K. E. Brighty. 1998. Chemistry and mechanism of action of the quinolone antibacterials, p. 29-80. in V. T. Andriole (ed.), The quinolones, 2nd ed. Academic Press, San Diego, Calif.
23. Hooper, D. C. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-341.
24. Hori, S., Y. Ohshita, Y. Utsui, and K. Hiramatsu. 1993. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 37:2278-2284.
25. Ince, D., and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2755-2764.
26. Ince, D., and D. C. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44:3344-3350.
27. Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2014-2023.
28. Kaatz, G. W., and S. M. Seo. 1997. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2733-2737.
29. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
30. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1991. Mechanism of fluoroquinolone resistance in Staphylococcus aureus. J. Infect. Dis. 163:1080-1086.
31. Kang, S. L., M. J. Rybak, B. J. McGrath, G. W. Kaatz, and S. M. Seo. 1994. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob. Agents Chemother. 38:2702-2709.
32. Lettieri, J., M. C. Rogge, L. Kaiser, R. M. Echols, and A. H. Heller. 1992. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36:993-996.
33. Levin, B. R., M. Lipsitch, V. Perrot, S. Schrag, R. Antia, L. Simonsen, N. M. Walker, and F. M. Stewart. 1997. The population genetics of antibiotic resistance. Clin. Infect. Dis. 24(Suppl. 1):S9-S16.
34. Maniatis, T. 1994. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, New York, N.Y.
35. Marchbanks, R. C., J. R. McKiel, D. H. Gilbert, N. J. Robillard, B. Painter, S. H. Zinner, and M. N. Dudley. 1993. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob. Agents Chemother. 37:1756-1763.
36. Miles, A. A., S. S. K. Misra, and J. O. Irwin. 1938. The estimation of the bactericidal power of the blood. J. Hyg. 38:732-749.
37. Morrissey, I., and J. T. Smith. 1994. The importance of oxygen in the killing of bacteria by ofloxacin and ciprofloxacin. Microbios 79:43-53.
38. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2002. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19:355-358.
39. Muñoz-Bellido, J. L., M. A. A. Manzanares, J. A. M. Andrés, M. N. G. Zufiaurre, G. Ortiz, M. S. Hernández, and J. A. García-Rodríguez. 1999. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob. Agents Chemother. 43:354-356.
40. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A, vol. 19. National Committee for Clinical Laboratory Standards, Wayne, Pa.
41. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, vol. 23. National Committee for Clinical Laboratory Standards, Wayne, Pa.
42. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
43. Pan, X. S., P. J. Hamlyn, R. Talens-Visconti, F. L. Alovero, R. H. Manzo, and L. M. Fisher. 2002. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones. Antimicrob. Agents Chemother. 46:2498-2506.
44. Piddock, L. J., Y. F. Jin, M. A. Webber, and M. J. Everett. 2002. Novel ciprofloxacin-resistant nalidixic acid-susceptible mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2276-2278.
45. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA 279:125-129.
46. Sanger, F. 1981. Determination of nucleotide sequences in DNA. Science 214:1205-1210.
47. Schentag, J. J., A. K. Meagher, and A. Forrest. 2003. Fluoroquinolone AUIC breakpoints and the link to bactericidal killing rates. Part 1: in vitro and animal models. Ann. Pharmacother. 37:1287-1298.
48. Schentag, J. J., A. K. Meagher, and A. Forrest. 2003. Fluoroquinolone AUIC breakpoints and the link to bactericidal killing rates. Part 2: human trials. Ann. Pharmacother. 37:1478-1488.
49. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles. Relationships between AUC above MIC and area under the inhibitory curve (AUIC) for cefmenoxime, ciprofloxacin, and tobramycin. DICP 25:1050-1057.
50. Schmitz, F. J., M. E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, A. Fluit, J. Verhoef, U. Hadding, H. P. Heinz, and K. Kohrer. 1998. Characterization of grlA, grlB, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252.
51. Shah, A., J. Lettieri, L. Kaiser, R. Echols, and A. H. Heller. 1994. Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. J. Antimicrob. Chemother. 33:795-801.
52. Shah, A., J. Lettieri, and D. Nix. 1995. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob. Agents Chemother. 39:1003-1006.
53. Spellberg, B., J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38:1279-1286.
54. Takahashi, H., T. Kikuchi, S. Shoji, S. Fijumura, A. Binte Lutfor, Y. Tokue, T. Nukiwa, and A. Watanabe. 1998. Characterization of gyrA, gyrB, grlA, and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 41:49-57.
55. Tanaka, M., Y. Onodera, Y. Uchida, and K. Sato. 1998. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:3044-3046.
56. 55a. Thomas, J. K., A. Forrest, S. M. Bhavanani, J. M. Hyatt, A. Cheng, C. H. Ballow, and J. J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
57. Wang, T., M. Tanaka, and K. Sato. 1998. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob. Agents Chemother. 42:236-240.
58. Wright, D. H., G. H. Brown, M. L. Peterson, and J. C. Rotschafer. 2000. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683.
59. Wright, D. H., V. K. Herman, F. N. Konstantinides, and J. C. Rotschafer. 1998. Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 709:97-104.
60. Yamagishi, J., T. Kojima, O. Yoshihiro, K. Fujimoto, H. Hattori, S. Nakamura, and M. Inoue. 1996. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1157-1163.
61. Yoshida, H., M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene which confers resistance to quinolones. J. Bacteriol. 172:6942-6949.
62. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.